Search for Terms or Answers
EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.
Read Article
At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD).
Read Article
Systemic autoimmune diseases are associated with increased cardiovascular morbidity and mortality – possibly through autonomic imbalance, myocardial inflammation, or fibrotic infiltration of the conduction system. A team in Colombia have been looking into the
Read Article
In an oral abstract presentation at EULAR 2026, results were shared from a longitudinal observational analysis of the EUSTAR database. The aim was to characterise organ involvement and disease progression – and time to these events – stratified by having a modified disease activity index (
Read Article
Throughout Gout Campaign Month, RheumNow is bringing together internationally recognized experts to explore the Systemic Burden of Gout through Rx Updates, QD Clinic case discussions, and expert Vlogs designed for practicing rheumatologists. New educational content will release https://t.co/ZOQQuZinQd
A pivotal member of the RheumNow family, Brenda McShan, will be retiring with honors.
Brenda has been RheumNow's graphic artist since we began in 2014. She has well-earned her retirement, and leaves behind a decade of great work, dedication and exceptional graphics. RheumNow's
Read Article
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.
Read Article
Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.
Read Article
New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children. The effort includes an update to the 2019 ACR/SAA/SPARTAN treatment guidelines focusing on adults,
Read Article
Real-world or observational data from registries, claims datasets, or electronic health records can enable us to perform large-scale analyses. These findings complement the insights gained from randomised trials, and can help to improve patient care and outcomes.1 As a key example
Read Article
JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses.
Read Article
A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain, drawing on 108 publications identified from a PubMed search (2005–2026) and the most recent guidelines from the WHO, ACP, and NICE.
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
